Postpartum Glycemia in Women at Risk For Persistent Hyperglycemia

  • STATUS
    Recruiting
  • End date
    Jun 29, 2023
  • participants needed
    40
  • sponsor
    University of Alabama at Birmingham
Updated on 29 November 2021
diabetes
insulin
oral glucose tolerance test
hyperglycemia
prenatal
glucose tolerance test
continuous glucose monitoring

Summary

GDM is characterized by decreased insulin sensitivity, decreased insulin secretion, or a combination of both. Women with GDM are at significant risk for overt T2DM later in life, and postpartum insulin sensitivity and secretion in women with GDM has not been quantified, limiting our ability to optimize screening for overt T2DM. In addition, compliance with currently recommended postpartum T2DM screening by OGTT is poor. Quantification of postpartum insulin sensitivity and secretion in women at high risk for T2DM will inform strategies to improve diagnostic strategies. Continuous glucose monitoring (CGM) is a new technology that may be useful to identify women with persistent hyperglycemia. Understanding maternal glycemia and physiology that drives glycemia in the postpartum period is limited. Completion of this study will define postpartum maternal glycemia, quantify insulin secretion versus insulin sensitivity defects, and demonstrate the feasiblity of using continuous glucose monitoring to identify women most at risk for overt T2DM.

Details
Condition Diabetes Prevention, Diabetes Mellitus Types I and II, Diabetes Mellitus, Gestational Diabetes, Diabetes (Pediatric), Pregnancy Complications
Treatment 2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor
Clinical Study IdentifierNCT04521712
SponsorUniversity of Alabama at Birmingham
Last Modified on29 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Live singleton gestation with no fetal anomalies at 34-40 weeks gestation
Gestational diabetes mellitus identified at >= 24 weeks' gestation requiring pharmacologic treatment (class A2)

Exclusion Criteria

History of prediabetes or polycystic ovarian syndrome
History of pregestational type 2 diabetes mellitus
Skin conditions which prevent wearing a continuous glucose monitor
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note